Search Result
Results for "
transgenic
" in MedChemExpress (MCE) Product Catalog:
7
Biochemical Assay Reagents
7
Isotope-Labeled Compounds
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
-
- HY-16950
-
|
(Z)-4-Hydroxytamoxifen; trans-4-Hydroxytamoxifen; (Z)-Afimoxifene
|
Estrogen Receptor/ERR
|
Cancer
|
|
4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .
|
-
-
- HY-123033A
-
|
|
Sirtuin
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside Chloride, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
|
-
-
- HY-13757
-
|
ICI 46474; (Z)-Tamoxifen Citrate; trans-Tamoxifen Citrate
|
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells.Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen Citrate activates autophagy and induces apoptosis. Tamoxifen Citrate can also be used to induce gene knockout in CreER transgenic mice .
|
-
-
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
-
-
- HY-152857
-
|
LY3473329
|
LDLR
|
Cardiovascular Disease
|
|
Muvalaplin (LY3473329) is an orally active, selective small molecule inhibitor of lipoprotein (a) (Lp (a)) that disrupts the initial non-covalent interaction between apo(a) and apoB100, preventing the disulphide bond and Lp(a)
formation. Muvalaplin reduces the levels of Lp (a) in transgenic mice and in cynomolgus monkeys .
|
-
-
- HY-103157
-
|
NSC168807
|
Autophagy
Ferroptosis
|
Cardiovascular Disease
|
|
PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
|
-
-
- HY-N6608
-
|
Eserine
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
|
-
-
- HY-B1266
-
|
Eserine salicylate
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
|
-
-
- HY-B0342
-
|
Methylglucamine; Meglumin; Methylglucamin
|
Biochemical Assay Reagents
|
Cancer
|
|
Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
-
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
-
- HY-20457
-
-
-
- HY-B0531
-
|
|
COX
Phosphodiesterase (PDE)
NF-κB
NO Synthase
Prostaglandin Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
|
-
-
- HY-123033
-
|
|
Sirtuin
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
|
-
-
- HY-12974
-
|
PRT318
|
Syk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
PRT-060318 (PRT318) s a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
|
-
-
- HY-B0957
-
|
Erythromycin ethyl succinate; EES
|
Bacterial
HIV
Autophagy
Antibiotic
|
Infection
|
|
Erythromycin Ethylsuccinate is an antibiotic useful for the treatment of a number of bacterial infections, has an antimicrobial spectrum similar to or slightly wider than that of penicillin. Erythromycin Ethylsuccinate has antiviral activity against HIV-1.
|
-
-
- HY-135470
-
|
P-7138
|
Bacterial
|
Infection
|
|
Nifurpirinol (P-7138) is a selective prosubstrate of bacterial nitroreductase (NTR). NTR catalyzes the reduction of nifurpirinol to generate cytotoxic metabolites that induce apoptosis in target cells. Nifurpirinol selectively ablates NTR-expressing cells such as pancreatic β cells, osteoblasts, dopaminergic neurons, and podocytes in transgenic zebrafish models. Nifurpirinol can be used in regeneration studies and disease modeling such as focal segmental glomerulosclerosis (FSGS) .
|
-
-
- HY-N4150
-
|
Quercetagetin-7-O-glucoside
|
Phosphatase
Tau Protein
NF-κB
|
Neurological Disease
Metabolic Disease
Inflammation/Immunology
|
|
Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
-
- HY-N1534
-
|
25-Deoxyecdysterone
|
Others
|
Others
|
|
Ponasterone A (25-Deoxyecdysterone), an ecdysteroid, has strong affinity for the ecdysone receptor. Ponasterone A is a potent regulator of gene expression in cells and transgenic animals, enabling reporter genes to be turned on and off rapidly .
|
-
-
- HY-157261
-
|
|
Biochemical Assay Reagents
|
Endocrinology
|
|
UNC2383 is an oligonucleotide enhancer compound. UNC2383 can enhance the efficacy of antisense oligonucleotides (ASOs) and splice-switching oligonucleotides (SSOs). UNC2383 can be used in research of diseases involving impaired oligonucleotide delivery, such as cystic fibrosis .
|
-
-
- HY-138669
-
|
|
PROTACs
Tau Protein
|
Neurological Disease
|
|
C004019 is a BBB-penetrable and small-molecule PROTAC that targets tau. C004019 can simultaneously recruit tau and E3 ligase, and effectively clear tau proteins by promoting the ubiquitination and proteasome-dependent degradation of tau, thereby improving synaptic and cognitive functions in Alzheimer's disease (AD) mice. C004019 can be used in the research of AD and tau protein-related diseases. (Pink: Ligand for target protein (HY-138679); Black: linker (HY-140189); Blue: E3 Ligase Ligand (HY-138678))
|
-
-
- HY-100384
-
NKL 22
1 Publications Verification
|
HDAC
|
Neurological Disease
Cancer
|
|
NKL 22 is a potent and selective inhibitor of histone deacetylases (HDAC), with IC50 values of 199 and 69 nM for HDAC1 and HDAC3, respectively. NKL 22 can reverse abnormal expression of HD‑related genes and restore the levels of key genes including Ppp1r1b in Huntington's disease transgenic mice. NKL 22 can be used for the researches of Huntington's disease and cancer .
|
-
-
- HY-145580
-
|
UCB0599; (R)-NPT200-11
|
α-synuclein
|
Neurological Disease
|
|
Minzasolmin (UCB0599; (R)-NPT200-11) is an orally active, blood-brain-permeable α-synuclein (α-Syn) inhibitor that selectively binds to α-Syn misfolded intermediates (such as oligomers) and inhibits aggregation and fibril formation by regulating their conformational stability. Minzasolmin can reduce the generation of pathological oligomers and block neurotoxic signaling, thereby reducing the abnormal accumulation of α-Syn in the brain. Minzasolmin significantly improved motor deficits, reduced neuroinflammatory markers, and α-Syn-related pathological deposition in transgenic mouse models .
|
-
-
- HY-W011151
-
|
|
Phytohormone
|
Others
|
|
trans-Zeatinriboside is a zeatin-type cytokinin and plant growth regulator. trans-Zeatinriboside is produced by the terrestrial filamentous cyanobacterium Nostoc sp. HK-01 and Agrobacterium tumefaciens (including Ti plasmid-dependent and Ti plasmid-independent strains). trans-Zeatinriboside is detectable as a cytokinin component in growing crown galls, and accumulates in large amounts in CHRK1-silenced transgenic tobacco accompanied by pleiotropic developmental abnormalities. trans-Zeatinriboside can be used in studies related to crown galls .
|
-
-
- HY-N2320
-
|
Eserine hemisulfate
|
Cholinesterase (ChE)
|
Neurological Disease
|
|
Physostigmine hemisulfate (Eserine hemisulfate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine hemisulfate can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine hemisulfate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine hemisulfate is also an antidote for anticholinergic poisoning .
|
-
-
- HY-123033C
-
|
|
Sirtuin
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside malate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside malate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside malate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
|
-
-
- HY-147008
-
|
|
Epigenetic Reader Domain
|
Cancer
|
|
XP-524 is a potent BET and EP300 inhibitor. XP-524 shows great tumoricidal activity in vivo. XP-524 prevents KRAS-induced, neoplastic transformation in vivo and extends survival in two transgenic mouse models of aggressive PDAC. XP-524 also enhances the presentation of self-peptide and tumor recruitment of cytotoxic T lymphocytes. XP-524 has the potential for the research of pancreatic ductal adenocarcinoma (PDAC) .
|
-
-
- HY-123033AR
-
|
|
Reference Standards
Sirtuin
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside (chloride) (Standard) is the analytical standard of Nicotinamide riboside (chloride). This product is intended for research and analytical applications. Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
|
-
-
- HY-154851
-
|
|
GSK-3
CDK
Tau Protein
|
Neurological Disease
|
|
GSK-3 inhibitor 3 is a selective, orally active and brain-penetrant inhibitor of GSK-3, with IC50s of 0.35 nM and 0.25 nM for GSK-3α and GSK-3β, respectively. GSK-3 inhibitor 3 lowers levels of tau protein phosphorylation at S396 in a triple-transgenic mouse Alzheimer’s disease model, with IC50 of 10 nM. GSK-3 inhibitor 3 can be used for neurological disease research .
|
-
-
- HY-124832
-
|
|
Caspase
Amyloid-β
|
Neurological Disease
|
|
δ-Secretase inhibitor 11 (compound 11) is an orally active, potent, BBB-penetrated, non-toxic, selective and specific δ-secretase inhibitor, with an IC50 of 0.7 μM. δ-Secretase inhibitor 11 interacts with both the active site and allosteric site of δ-secretase. δ-Secretase inhibitor 11 attenuates tau and APP (amyloid precursor protein) cleavage. δ-Secretase inhibitor 11 ameliorates synaptic dysfunction and cognitive impairments in tau P301S and 5XFAD transgenic mouse models. δ-Secretase inhibitor 11 can be used for Alzheimer's disease research .
|
-
-
- HY-145313
-
|
|
Tau Protein
|
Neurological Disease
|
|
TTBK1-IN-2 (compound 29) is a potent Tau-Tubulin kinase (TTBK1) inhibitor with IC50s of 0.24 and 4.22 µM, respectively. TTBK1-IN-2 reveals good brain penetration in vivo and is able to reduce TDP-43 phosphorylation not only in cell cultures but also in the spinal cord of transgenic TDP-43 mice .
|
-
-
- HY-N0542
-
|
|
Bacterial
|
Cardiovascular Disease
Infection
Neurological Disease
Cancer
|
|
Pseudoginsenoside RT5 is an orally active ocotillol-type ginsenoside and Antibacterial agent. Pseudoginsenoside RT5 can be isolated from American ginseng, transgenic American ginseng crown gall tumors and Panax japonicus. Pseudoginsenoside RT5 exerts cardioprotective effects against myocardial injury, and also possesses antibacterial and antitumor activities. Pseudoginsenoside RT5 can be used in research related to Alzheimer's disease, myocardial injury, tumors and bacterial infections .
|
-
-
- HY-110002
-
LFM-A13
1 Publications Verification
|
Polo-like Kinase (PLK)
Btk
JAK
|
Cancer
|
|
LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research
|
-
-
- HY-125287
-
|
(Rac)-UCB0599; NPT200-11
|
α-synuclein
|
Neurological Disease
|
|
(Rac)-Minzasolmin ((Rac)-UCB0599; NPT200-11) is a blood-brain barrier penetrated alpha-synuclein (ASYN) misfolding inhibitor. (Rac)-Minzasolmin acts on the early stage of ASYN aggregation process, by replacing the membrane-bound oligomers ASYN, allowing them to revert to the monomeric form, while preventing pathological aggregation. (Rac)-Minzasolmin effectively improves the ASYN deposition in the retina and the neuro-pathological indicators in two α-synuclein transgenic mouse models. (Rac)-Minzasolmin can be used for the studies of Parkinson's disease (PD) and dementia with Lewy bodies (DLB) .
|
-
-
- HY-143792
-
|
|
Huntingtin
P-glycoprotein
|
Neurological Disease
|
|
HTT-D3 is an orally active, blood-brain barrier penetrant splicing modulator of huntingtin (HTT). HTT-D3 promotes the inclusion of a pseudo-exon containing a premature termination codon into HTT pre-mRNA, triggers nonsense-mediated mRNA degradation and reduces HTT protein levels. HTT-D3 induces dose-dependent, comparable reductions in mutant HTT protein in both the brain and peripheral tissues of transgenic mouse models. HTT-D3 can be used for the research of Huntington's disease .
|
-
-
- HY-101954
-
|
ORI-9020; SB-9000
|
HBV
|
Infection
|
|
Inarigivir (ORI-9020) is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) act as a RIG-I agonist to activate cellular innate immune responses .
|
-
-
- HY-101954A
-
|
ORI-9020 ammonium; SB-9000 ammonium
|
HBV
|
Infection
Inflammation/Immunology
|
|
Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses .
|
-
-
- HY-123033B
-
|
|
Sirtuin
Endogenous Metabolite
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside tartrate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside tartrate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside tartrate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
|
-
-
- HY-12372
-
|
|
IAP
Caspase
|
Cancer
|
|
Sanggenon G is a cell-permeable and potent inhibitor of X-linked inhibitor of apoptosis protein (XIAP). Sanggenon G binds specifically to the BIR3 domain of XIAP with a binding affinity of 34.26 μM. Sanggenon G enhances caspase activation .
|
-
-
- HY-174790
-
|
|
mRNA
|
Cancer
|
|
Firefly Luciferase mRNA is a reporter mRNA that can be transfected into cells to express firefly luciferase protein. Firefly Luciferase mRNA induces cytotoxicity in cancer cells at low concentrations. In cancer cells, the expression level of luciferase shows a non-linear relationship with the dose of Firefly Luciferase mRNA. When combined with the H2S-responsive bioluminescent probe (H-Luc), Firefly Luciferase mRNA enables bioluminescence-based detection of endogenous hydrogen sulfide in non-transgenic NAFLD cell models and NAFLD mouse models. Firefly Luciferase mRNA can be used in studies related to non-alcoholic fatty liver disease .
|
-
-
- HY-P4885
-
|
AβpE3-40
|
Amyloid-β
|
Neurological Disease
|
|
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .
|
-
-
- HY-125172
-
|
Polyglutamine Aggregation inhibitor III
|
Huntingtin
|
Others
|
|
C2-8 is an inhibitor of polyglutamine (polyQ) aggregation (IC50s=25 and 0.05 μM for recombinant HDQ51 and in PC12 cells, respectively). It also inhibits polyQ aggregation in organotypic hippocampal slice cultures isolated from R6/2 transgenic mice and reduces neurodegeneration in a dose-dependent manner in a Drosophila model of Huntington's disease. C2-8 (100 and 200 mg/kg) reduces huntingtin aggregate size, reduces neuronal atrophy, and improves motor performance in a rotarod test in the R6/2 transgenic mouse model of Huntington's disease.
|
-
-
- HY-139973
-
|
|
Amyloid-β
|
Neurological Disease
|
|
OAB-14, is a Bexarotene (HY-14171) derivative, improves Alzheimer's disease-related pathologies and cognitive impairments by increasing β-amyloid clearance in APP/PS1 mice. OAB-14 effectively ameliorates the dysfunction of the endosomal-autophagic-lysosomal pathway in APP/PS1 transgenic mice .
|
-
-
- HY-N1414A
-
|
|
Bcl-2 Family
Apoptosis
|
Neurological Disease
|
|
3′,6-Disinapoylsucrose is a type of oligosaccharide that's effective when taken orally, and it has antidepressant, anti-anxiety, and antioxidant properties. 3′,6-Disinapoylsucrose inhibits neuronal apoptosis by lowering the ratio of Bax to Bcl-2 in hippocampal neurons, and it enhances cognitive function in APP/PS1 transgenic mice by activating the CREB/BDNF signaling pathway .
|
-
-
- HY-175988
-
|
|
DNA Methyltransferase
HDAC
|
Cancer
|
|
DNMT/HDAC-IN-2 (Compound Y7) is a DNMT and HDAC inhibitor with IC50 values for DNMT1, HDAC1, and HDAC6 of 365, 0.2, and 8.91 nM respectively. DNMT/HDAC-IN-2 inhibits the proliferation of breast cancer cells. DNMT/HDAC-IN-2 significantly reduces tumor growth in xenografts and transgenic breast cancer mouse models. DNMT/HDAC-IN-2 can be used for the study of breast cancer .
|
-
-
- HY-165061
-
|
Sciadonic acid
|
Apolipoprotein
|
Inflammation/Immunology
|
|
5(Z),11(Z),14(Z)-Eicosatrienoic acid (Sciadonic acid), a polyunsaturated fatty acid sourced from maritime pine seed oil, gymnospermae leaves and seeds, and freshwater gastropods, has been shown to reduce high-density lipoprotein and ApoA1 levels in transgenic mice expressing human ApoA1 when included in their diet. In vitro studies indicate that it diminishes cholesterol efflux, and when applied topically in its methyl ester form, it alleviates inflammatory processes, likely by displacing arachidonic acid from phospholipid pools and lowering concentrations of downstream inflammatory mediators such as prostaglandin E2 and leukotrienes.
|
-
-
- HY-174795
-
|
|
mRNA
|
Others
|
|
mCherry mRNA encodes the mCherry fluorescent protein, which is derived from Anaplasma marginale. mCherry can be used as a fluorescent tracer in transfection and transgenic experiments or as a reporter of gene expression.
|
-
-
- HY-123033D
-
|
|
Endogenous Metabolite
Sirtuin
|
Neurological Disease
Metabolic Disease
Cancer
|
|
Nicotinamide riboside triflate, an orally active NAD + precursor, increases NAD + levels and activates SIRT1 and SIRT3. Nicotinamide riboside triflate is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities . Nicotinamide riboside triflate reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease .
|
-
-
- HY-P991307
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
-
-
- HY-P1787
-
|
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .
|
-
-
- HY-156842
-
|
|
Amyloid-β
|
Neurological Disease
|
|
MCAAD-3 is a near-infrared Aβ imaging probe with blood-brain barrier penetrability. MCAAD-3 has a strong affinity for Aβ polymers (Ki >106 nM) and can label Aβ plaques in the brains of transgenic mice .
|
-
- HY-122989
-
|
|
DYRK
|
Inflammation/Immunology
|
|
Aristolactam BIII is a potent DYRK1A inhibitor and inhibits the kinase activity of DYRK1A in vitro (IC50= 9.67 nM. Aristolactam BIII rescues the proliferative defects of DYRK1A transgenic (TG) mouse-derived fibroblasts and neurological and phenotypic defects of DS-like Drosophila models .
|
-
- HY-N6608S
-
|
Eserine-d3
|
Isotope-Labeled Compounds
Cholinesterase (ChE)
|
Neurological Disease
|
|
Physostigmine-d3 is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
|
-
- HY-164547
-
|
|
Porcupine
Wnt
β-catenin
|
Cancer
|
WHN-88 is a Porcupine (PORCN) inhibitor. WHN-88 can eliminate the palmitoylation of Wnt ligands, preventing their secretion and subsequent Wnt/β-catenin signaling. WHN-88 can inhibit cancer cell stemness and suppress the occurrence and development of breast tumors in MMTV-Wnt1 transgenic mice .
|
-
- HY-16950R
-
|
(Z)-4-Hydroxytamoxifen (Standard); trans-4-Hydroxytamoxifen (Standard); (Z)-Afimoxifene (Standard)
|
Estrogen Receptor/ERR
Reference Standards
|
Cancer
|
|
4-Hydroxytamoxifen (Standard) is the analytical standard of 4-Hydroxytamoxifen. This product is intended for research and analytical applications. 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is an orally active, selective estrogen receptor modulator (SERM). 4-Hydroxytamoxifen ((Z)-4-Hydroxytamoxifen) is also the active metabolic form of Tamoxifen (HY-13757A) in vivo and can be used to induce gene knockout in transgenic mice expressing CreER .
|
-
- HY-20457G
-
|
|
Toll-like Receptor (TLR)
Bacterial
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-169421
-
|
|
Sodium Channel
|
Cancer
|
|
Nav1.7-IN-18 (Compound 31) is a Nav1.7 inhibitor with a Ki value of 4.9 nM and an IC50 of 13 nM, showing analgesic effects in transgenic mice with inherited erythromelalgia (IEM) .
|
-
- HY-171953
-
|
|
Liposome
|
Others
|
|
THP1 Lipid is an ionizable lipidoid. THP1 Lipid can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to muscles with minimal toxicity and editing genes in specific liver tissues in tdTomato transgenic mice model. THP1 Lipid can be used for vaccine delivery and CRISPR/Cas9-mediated gene editing research .
|
-
- HY-103157R
-
|
NSC168807 (Standard)
|
Reference Standards
Autophagy
Ferroptosis
|
Cardiovascular Disease
|
|
PD146176 (Standard) is the analytical standard of PD146176. This product is intended for research and analytical applications. PD146176 (NSC168807), a 15-Lipoxygenase (15-LO) inhibitor, inhibits rabbit reticulocyte 15-LO (Ki=197 nM, IC50=0.54 μM). PD146176 reverses cognitive impairment, brain amyloidosis, and tau pathology by stimulating autophagy in aged triple transgenic mice .
|
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
- HY-50884
-
-
- HY-P1735
-
-
- HY-163913
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-IN-5 (compound 49) is a highly selective, nonpeptidic and noncovalent 3CL pro inhibitor with IC50s of 38 nM, 21.1 nM and 86 nM for 3CL pro of SARS-CoV-1, SARS-CoV-2, Bat coronavirus WIV1, respectively. SARS-CoV-IN-5 inhibits the replication of the SARS-CoV-2 delta variant with an EC50 of 0.272 μM. SARS-CoV-IN-5 significantly reduces the lung viral copies in a K18-hACE2 transgenic mouse model. SARS-CoV-IN-5 has good target-specific and potential broad-spectrum anticoronavirus activities against SARS-CoV-1, WIV1, MERS, HCoV-OC43, HCoV-229E, and HKU9 .
|
-
- HY-147706
-
|
|
Others
|
Cancer
|
|
Ar524 has higher inhibitory activity than the known transgenic inhibitor kifunensine. At the same time, ar524 inhibited low concentration (10 μ M) Spheroid formation of human malignant cells.
|
-
- HY-149430
-
|
|
Amyloid-β
|
Neurological Disease
|
|
YIAD-0205 is an orally available Aβ(1?42) aggregation inhibitor. YIAD-0205 demonstrated in vivo efficacy in an AD transgenic mouse model with five familial AD mutations (5XFAD) .
|
-
- HY-164510
-
|
|
Cytochrome P450
|
Others
|
|
N-Formyldemecolcine is a colchicine precursor that contains the characteristic tropolone ring and pharmacophore of colchicine. N-Formyldemecolcine can be synthesized de novo by genetically engineering transgenic Nicotiana benthamiana and atypical cytochrome P450s that catalyze the production of colchicine's unique carbon scaffold .
|
-
- HY-172503
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
- HY-172503A
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG3400-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG3400-KAA can be used for drug delivery .
|
-
- HY-169224
-
|
|
SARS-CoV
|
Infection
|
|
SARS-CoV-2-IN-100 (Compound 172) is an inhibitor of SARS-CoV-2, demonstrating broad-spectrum antiviral activity against various SARS-CoV-2 variants. SARS-CoV-2-IN-100 exhibits synergistic effects with Nirmatrelvir, which can reduce the risk of antiviral drug resistance .
|
-
- HY-118543
-
|
|
HIF/HIF Prolyl-Hydroxylase
|
Cardiovascular Disease
|
|
TM6089 is a unique Prolyl Hydroxylase (PHD) inhibitor which stimulates HIF activity without iron chelation and induces angiogenesis and exerts organ protection against ischemia. Local administration of TM6089 enhances angiogenesis, and oral administration stimulates HIF activity in transgenic rats expressing a hypoxia-responsive reporter vector .
|
-
- HY-B0342R
-
|
Methylglucamine (Standard); Meglumin (Standard); Methylglucamin (Standard)
|
Biochemical Assay Reagents
Reference Standards
|
Cancer
|
|
Meglumine (Standard) is the analytical standard of Meglumine. This product is intended for research and analytical applications. Meglumine (Methylglucamine) is an orally active amino sugar derived from sorbitol. Meglumine has anti-inflammatory and antitumor activity. Meglumine is often used as an excipient in active molecules and with iodinated compounds in contrast agents such as meglumine and meglumine iodide .
|
-
- HY-B1266R
-
|
Eserine salicylate (Standard)
|
Reference Standards
Cholinesterase (ChE)
|
Neurological Disease
|
|
Physostigmine (salicylate) (Standard) is the analytical standard of Physostigmine (salicylate). This product is intended for research and analytical applications. Physostigmine salicylate (Eserine salicylate) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine salicylate crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine salicylate can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine salicylate is also an antidote for anticholinergic poisoning .
|
-
- HY-135470R
-
|
P-7138 (Standard)
|
Reference Standards
Bacterial
|
Infection
|
|
Nifurpirinol (P-7138) (Standard) is the analytical standard of Nifurpirinol (HY-135470). This product is intended for research and analytical applications. Nifurpirinol (P-7138) is a selective prosubstrate of bacterial nitroreductase (NTR). NTR catalyzes the reduction of nifurpirinol to generate cytotoxic metabolites that induce apoptosis in target cells. Nifurpirinol selectively ablates NTR-expressing cells such as pancreatic β cells, osteoblasts, dopaminergic neurons, and podocytes in transgenic zebrafish models. Nifurpirinol can be used in regeneration studies and disease modeling such as focal segmental glomerulosclerosis (FSGS) .
|
-
- HY-123357
-
|
|
Apoptosis
|
Neurological Disease
|
|
IMM-H004, a coumarin derivative, possesses neuroprotective and potent free radical scavenging abilities. IMM-H004 significantly inhibits amyloid-β (Aβ)-induced cytotoxicity and apoptosis, offering potential value for research into neurodegenerative diseases such as Alzheimer's disease. Additionally, IMM-H004 is also capable of effectively blocking the calcium mobilization and chemotaxis induced by CKLF1-C27 (HY-P3418), thereby alleviating asthmatic pathological changes in the lung tissue of CKLF1 transgenic mice .
|
-
- HY-118264
-
|
|
Angiotensin-converting Enzyme (ACE)
Neprilysin
|
Cardiovascular Disease
|
|
MDL-100240 is a dual-acting angiotensin-converting enzyme (ACE) and neutral endopeptidase (NEP) inhibitor. MDL-100240 can significantly lower blood pressure, reverse left ventricular hypertrophy, and effectively prevent hypertrophy and dilatation of the aorta and resistance arteries, with an effect comparable to that of ramipril (HY-B0279). In addition, MDL-100240 can also reduce aldosterone levels, but has no significant effect on atrial natriuretic peptide and cGMP. In 3-month-old transgenic rats, MDL-100240 can reduce adrenomedullin concentrations, prevent and reverse severe hypertension and cardiovascular damage, and enhance bradykinin effects.
|
-
- HY-B0531S
-
|
|
Isotope-Labeled Compounds
COX
NF-κB
Phosphodiesterase (PDE)
NO Synthase
Prostaglandin Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
|
-
- HY-B0531R
-
|
|
Reference Standards
COX
Phosphodiesterase (PDE)
NF-κB
NO Synthase
Prostaglandin Receptor
|
Infection
Neurological Disease
Inflammation/Immunology
Cancer
|
|
Triflusal (Standard) is the analytical standard of Triflusal (HY-B0531). This product is intended for research and analytical applications. Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
|
-
- HY-13757AS1
-
|
ICI 47699-d3; (Z)-Tamoxifen-d3; trans-Tamoxifen-d3
|
Isotope-Labeled Compounds
Estrogen Receptor/ERR
Apoptosis
Autophagy
HSP
|
Cancer
|
|
Tamoxifen-d3 is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-118243
-
|
|
Amyloid-β
|
Others
|
|
KMS88009 is a potent small molecule that directly interferes with the formation of amyloid-β oligomers, thereby preserving cognitive behavior when used preventively and reversing cognitive behavior decline when used therapeutically. Oral administration of KMS88009 around the onset of Alzheimer's disease symptoms significantly reduced the assembly of amyloid-β oligomers and improved cognitive behavior in the APP/PS1 double transgenic mouse model. This unique dual mode of action suggests that KMS88009 may be a powerful therapeutic candidate for the treatment of Alzheimer's disease. In an evaluation, the physicochemical properties, pharmacokinetics and toxicity of this anti-amyloidogenic small molecule KMS88009 were studied, as well as post-mortem analysis of APP/PS1 TG mice after behavioral testing.
|
-
- HY-W778408
-
|
ICI 47699-13C6; (Z)-Tamoxifen-13C6; trans-Tamoxifen-13C6
|
Isotope-Labeled Compounds
Apoptosis
Autophagy
HSP
Estrogen Receptor/ERR
|
Endocrinology
|
|
Tamoxifen- 13C6 (ICI 47699- 13C6) is the 13C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .
|
-
- HY-182648
-
|
|
ASK1
|
Neurological Disease
|
|
K811 is an orally active ASK1 inhibitor with an IC50 of 6 nM. K811 inhibits glial cell activation in the lumbar spinal cord of SOD1 G93A transgenic mice. K811 extends the survival of SOD1 G93A transgenic mice, a mouse model of amyotrophic lateral sclerosis. K811 can be used in studies related to amyotrophic lateral sclerosis .
|
-
- HY-P992484
-
|
|
Tau Protein
|
Neurological Disease
|
|
VY7523 is a monoclonal antibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
- HY-12974A
-
|
PRT318 dihydrochloride
|
Syk
Apoptosis
|
Inflammation/Immunology
Cancer
|
|
PRT-060318 (PRT318) dihydrochloride is a potent, selective and orally active tyrosine kinase Syk inhibitor with an IC50 of 3 nM. PRT-060318 dihydrochloride suppresses chronic lymphocytic leukemia (CLL) B cell activation and migration, and induces apoptosis. PRT-060318 dihydrochloride prevents Heparin (HY-17567)-induced thrombocytopenia and thrombosis in a transgenic mouse model. PRT-060318 dihydrochloride can be used for CLL and thrombus research .
|
-
- HY-139499
-
|
|
DNA/RNA Synthesis
|
Cancer
|
|
Sudemycin D6 is a pre-mRNA splicing modulator with potent antitumour activity. Sudemycin D6 changes splice site usage of the DUSP11 and SRRM1 pre-mRNA. Sudemycin D6 reduces survival and alters cell cycle in haematopoietic cells expressing mutant U2AF1. Sudemycin D6 attenuates mutant U2AF1-induced haematopoietic progenitor cell expansion in U2AF1(S34F) transgenic mice. Sudemycin D6 can be used for cancer research .
|
-
- HY-182325
-
|
|
Proteasome
Interleukin Related
|
Neurological Disease
|
|
DB-310 is a selective immunoproteasome LMP2 inhibitor with an IC50 value of 80.62 nM. DB-310 inhibits the production of IL-1α in microglia. DB-310 improves cognitive function in the Tg2576 transgenic mouse model of Alzheimer's disease. DB-310 can be used for research related to Alzheimer's disease .
|
-
- HY-183933
-
|
|
ASK1
|
Neurological Disease
|
|
K812 is an orally active ASK1 inhibitor with a 6 nM IC50 against ASK1. K812 selectively inhibits ASK1 activation. K812 inhibits glial activation in the lumbar spinal cord. K812 extends survival of SOD1 G93A transgenic mice. K812 can be used for the research of amyotrophic lateral sclerosis .
|
-
- HY-182304
-
|
|
Amyloid-β
α-synuclein
Amylin Receptor
Tau Protein
SOD
|
Neurological Disease
|
|
CLR01 sodium is a blood-brain barrier-permeable anti-aggregation agent. CLR01 sodium inhibits the de novo aggregation of Amyloid-β 40/42, α-synuclein, IAPP, tau protein and SOD1. CLR01 sodium reduces amyloid plaque burden in the cortex of triple-transgenic mice and improves the memory and motor abilities of these mice. CLR01 sodium can be used in research related to Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis (ALS) .
|
-
- HY-183068
-
|
|
NEKs
CDK
Discoidin Domain Receptor
EGFR
PI3K
|
Cancer
|
|
AP4-43 is an orally active CLK1, CLK4, PI3K, DDR1, EGFR and NEK4 inhibitor. AP4-43 reduces growth of mammalian colorectal cancer organoids. AP4-43 improves survival in a transgenic Drosophila model of KRAS-mutant colorectal cancer. AP4-43 can be used for the research of KRAS-mutant colorectal cancer .
|
-
- HY-182429
-
|
|
Beta-secretase
Cathepsin
Amyloid-β
|
Neurological Disease
|
|
NB-533 is an orally active and brain-penetrant BACE-1 inhibitor with a human IC50 of 0.002 μM. NB-533 also inhibits human cathepsin D with an IC50 of 0.001 μM. NB-533 inhibits amyloidogenic amyloid precursor protein (APP) processing and reduces Aβ40 release. NB-533 reduces brain levels of APP metabolite C99 and Aβ40 in transgenic mice. NB-533 can be used for the research of Alzheimer’s disease .
|
-
- HY-182456
-
|
|
KMO
|
Neurological Disease
|
|
CHDI-340246 is an orally active kynurenine monooxygenase (KMO) inhibitor. CHDI-340246 blocks KMO activity, alters the metabolic flux of the kynurenine pathway, inhibits the production of 3-hydroxykynurenine and quinolinic acid, elevates the levels of kynurenine and kynurenic acid, and restores electrophysiological abnormalities in transgenic mouse models of Huntington's disease. CHDI-340246 can be used in studies related to Huntington's disease .
|
-
- HY-P991918
-
|
IgG2-AAS
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
KHK2840 is a potent CD40 agonist with a Kd value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma .
|
-
- HY-N19612
-
|
|
Ser/Thr Protease
|
Others
|
|
Proteasefrom aspergillus oryzae is a serine protease identified in the non-transgenic Aspergillus ochraceus strain AE-P. Proteasefrom aspergillus oryzae functions as a food enzyme and catalyzes protein hydrolysis with broad-spectrum specificity .
|
-
- HY-172504
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG5000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG5000-KAA can be used for drug delivery .
|
-
- HY-172502
-
|
|
Liposome
|
Cancer
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
-
- HY-P991528
-
|
|
NF-κB
|
Inflammation/Immunology
Cancer
|
|
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
|
-
- HY-N17667
-
|
|
Others
|
Others
|
|
6’’-O-trans-p-Coumaroylgenipin gentiobioside (compound 2) is an iridoid glucoside that can be found in Gardenia jasminoides .
|
-
- HY-101954AR
-
|
ORI-9020 ammonium (Standard); SB-9000 ammonium (Standard)
|
Reference Standards
HBV
|
Infection
Inflammation/Immunology
|
|
Inarigivir ammonium (Standard) is the analytical standard of Inarigivir ammonium (HY-101954A). This product is intended for research and analytical applications. Inarigivir (ORI-9020) ammonium is a dinucleotide antiviral drug that can significantly reduce liver HBV DNA in transgenic mice expressing hepatitis B virus. Inarigivir (ORI-9020) ammonium acts as a RIG-I (Retinoic acid-inducible gene-I) agonist to activate cellular innate immune responses .
|
-
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
- HY-120116
-
|
|
PI3K
Akt
|
Inflammation/Immunology
|
|
AM-8508 is an orally bioactive PI3Kδ inhibitor with an IC50 of 0.016 μM. AM-8508 selectively inhibits PI3Kδ, thereby blocking AKT phosphorylation mediated by the B cell receptor. AM-8508 suppresses the formation of antigen-specific IgG and IgM in rats immunized with keyhole limpet hemocyanin. AM-8508 can be used for the research of inflammatory diseases .
|
-
- HY-P992455
-
|
|
CD38
Fc Receptor (FcR)
Apoptosis
|
Cancer
|
|
SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma .
|
-
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
- HY-N4150R
-
|
Quercetagetin-7-O-glucoside (Standard)
|
Reference Standards
Phosphatase
Tau Protein
NF-κB
|
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Quercetagitrin (Standard) is the analytical standard of Quercetagitrin. This product is intended for research and analytical applications. Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
- HY-156397
-
|
|
AMPK
YAP
|
Cancer
|
|
HTH-02-006 is a NUAK2 inhibitor, with an IC50 value of 126 nM. HTH-02-006 inhibits NUAK2-mediated signaling by reducing phosphorylation of its substrate MYPT1 at S445 and downstream MLC. HTH-02-006 shows growth inhibitory efficacy in YAP-high cancer cells (HuCCT-1, SNU475). HTH-02-006 significantly suppresses YAP-induced hepatomegaly (reduced liver/body weight ratio) in TetO-YAP S127A transgenic mice and demonstrates significant anti-tumor efficacy in mice bearing HMVP2 prostate cancer allografts. HTH-02-006 can be used for the study of liver cancer and prostate cancer .
|
-
- HY-13757AR
-
|
ICI 47699(Standard); (Z)-Tamoxifen(Standard); trans-Tamoxifen (Standard)
|
Reference Standards
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Endocrinology
Cancer
|
|
Tamoxifen (Standard) is the analytical standard of Tamoxifen (HY-13757A). This product is intended for research and analytical applications. Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-13757S
-
|
ICI 46474-d3 hydrochloride; (Z)-Tamoxifen-d3 hydrochloride; trans-Tamoxifen-d3 hydrochloride
|
Apoptosis
Estrogen Receptor/ERR
Autophagy
HSP
Isotope-Labeled Compounds
|
Cancer
|
|
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-13757R
-
|
ICI 46474 (Standard); (Z)-Tamoxifen Citrate (Standard); trans-Tamoxifen Citrate (Standard)
|
Reference Standards
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Cancer
|
|
Tamoxifen (Citrate) (Standard) is the analytical standard of Tamoxifen (Citrate). This product is intended for research and analytical applications. Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
- HY-124187
-
|
Ethyl pinolenate
|
Biochemical Assay Reagents
|
Others
|
|
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
|
-
- HY-13757A
-
Tamoxifen
Maximum Cited Publications
229 Publications Verification
ICI 47699; (Z)-Tamoxifen; trans-Tamoxifen
|
Estrogen Receptor/ERR
HSP
Autophagy
Apoptosis
|
Infection
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells. Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively. Tamoxifen activates autophagy and induces apoptosis. Tamoxifen can also be dissolved in corn oil (HY-Y1888) for use in inducing gene knockout in CreER transgenic mice. Tamoxifen has better solubility in corn oil compared to Tamoxifen Citrate (HY-13757) .
|
-
- HY-135115
-
|
3,4-DHPEA-EA
|
α-synuclein
HDAC
Adrenergic Receptor
|
Inflammation/Immunology
|
|
Oleuropein Aglycone (3,4-DHPEA-EA) is a polyphenol and the aglycone form of oleuropein (HY-N0292), formed by enzymatic, acidic or acetylated hydrolysis of oleuropein. Dietary intake of oleuropein Aglycone (50 mg/kg diet) increases the number of neuronal autophagic vesicles, reverses cognitive deficits in the TgCRND8 transgenic mouse model of Alzheimer's disease, and reduces the levels of histone deacetylase 2 (HDAC2) in the cortex and hippocampus. Oleuropein Aglycone increases urinary norepinephrine, interscapular brown adipose tissue epinephrine, and UCP1 protein levels, and reduced plasma leptin levels and total abdominal adipose tissue weight in a rat model of high-fat diet-induced obesity. Oleuropein Aglycone also reduced lung neutrophil infiltration, lipid peroxidation, and IL-1β levels in a mouse model of carrageenan-induced pleurisy.
|
-
- HY-170524
-
|
|
SARS-CoV
DNA Methyltransferase
Cytochrome P450
|
Infection
|
|
TDI-015051 is a highly selective, orally active antiviral agent that targets the coronavirus NSP14 guanine-N7 methyltransferase. TDI-015051 binds to substrates in a non-competitive manner and forms a stable ternary complex, precisely blocking the capping and methylation processes of viral mRNA. TDI-015051 potently inhibits a variety of coronaviruses (including SARS-CoV-2 and MERS). By impairing viral replication and translation and inducing a moderate type I interferon-mediated immune response, it significantly reduces pulmonary viral load and exhibits a synergistic effect with Nirmatrelvir (HY-138687). In addition, TDI-015051 does not inhibit non-coronavirus methyltransferases, and the drug-resistant mutations it induces impair viral fitness, demonstrating excellent antiviral properties and safety. TDI-015051 can be used for research on COVID-19 and the replication mechanism of coronaviruses .The IC50 values of TDI-015051 against SARS-CoV-2, α-hCoV-NL63, α-hCoV-229E, β-hCoV-MERS are 0.15 nM, 1.7 nM, 2.6 nM and 3.6 nM, respectively, and the Ka value against SARS-CoV-2 is 0.061 nM .
|
-
- HY-167832
-
|
|
JNK
SGK
ROCK
Tau Protein
MMP
DNA/RNA Synthesis
Pyruvate Kinase
NF-κB
COX
NO Synthase
Reactive Oxygen Species (ROS)
|
Neurological Disease
Cancer
|
|
PT109 is an orally active, blood-brain barrier permeable multi-kinase inhibitor. By inhibiting PTBP1, PT109 promotes the switch of pyruvate kinase isoform from PKM2 to PKM1, thereby effectively inhibiting the proliferation and migration of glioblastoma multiforme and inducing its reprogramming into oligodendrocytes. PT109 also targets and regulates key signaling molecules such as JNK, SGK1, GSK3β to exert neuroprotective effects including promoting neurogenesis, inducing synapse formation and alleviating neuroinflammation. In Alzheimer's disease models, PT109 exhibits significant efficacy in improving spatial learning ability, along with excellent in vivo pharmacokinetic properties. PT109 can be used to investigate metabolic reprogramming of glioblastoma multiforme and neuroprotective mechanisms of Alzheimer's disease .
|
-
- HY-120257
-
|
|
Caspase
Apoptosis
|
Cardiovascular Disease
|
|
IDN-1965 is an irreversible, broad-spectrum caspase inhibitor. IDN-1965 prevents downstream apoptotic events (such as DNase activation) and significantly delays cytochrome c release by inhibiting caspase activity. IDN-1965 significantly delayed death in mice with cardiomyocyte apoptosis. IDN-1965 completely prevents left ventricular dilation, systolic dysfunction, and fibrosis in mice with dilated cardiomyopathy. IDN-1965 can be used to study apoptosis-related diseases such as heart failure and the mechanisms of apoptosis initiation .
|
-
- HY-P11677
-
|
|
|
Neurological Disease
|
|
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .
|
-
- HY-137276
-
|
Bluo-Gal
|
Fluorescent Dye
Glycosidase
|
Others
|
|
5-Bromo-3-indolyl β-D-galactopyranoside (Bluo-Gal) is a chromogenic substrate for β-galactosidase. 5-Bromo-3-indolyl β-D-galactopyranoside is hydrolyzed by the enzyme to generate a 5-bromoindole intermediate, which is further oxidized to form an insoluble blue precipitate. 5-Bromo-3-indolyl β-D-galactopyranoside can specifically recognize bacterial β-galactosidases (such as the product of the Escherichia coli lacZ gene) and reacts at pH 7.4, making it suitable for light and electron microscopic observations. 5-Bromo-3-indolyl β-D-galactopyranoside can be used in histochemical detection of reporter gene expression in transgenic organisms, such as the localization analysis of β-galactosidase activity in mouse embryos or muscle tissues .
|
-
- HY-175748
-
-
- HY-P992156
-
|
|
LAG-3
|
Cancer
|
|
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal antibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer .
|
-
- HY-165603
-
|
|
Liposome
VEGFR
FGFR
|
Cardiovascular Disease
Inflammation/Immunology
Cancer
|
|
Si5-N14 is a key component of siloxane-incorporated lipid nanoparticles (SiLNP), possessing pro-vascular repair and anti-tumor activities. In the transgenic GFP mouse model, Si5-N14 can mediate CRISPR-Cas9 editing. In the Lewis lung carcinoma (LLC) tumor-bearing mouse model, Si5-N14 can knock out the expression of Vascular Endothelial Growth Factor Receptor 2 (VEGFR2) to exert an anti-tumor effect. In a mouse model of lung injury induced by viral infection, the delivery of Fibroblast Growth Factor-2 (FGF-2) mRNA via Si5-N14 can promote vascular repair, increase blood oxygen levels, and improve lung function. Si5-N14 shows promise for research in the fields of oncology, pneumonia, and cardiovascular diseases .
|
-
- HY-157269
-
|
|
Hapten
|
Inflammation/Immunology
|
|
J10-1 is a hapten small molecule. J10-1 accelerates peptide exchange in MHC class II molecules in an HLA-DM-independent manner, and its effect is not affected by the polymorphism of the P1 pocket of MHC class II molecules. J10-1 enhances the processes of peptide dissociation, peptide binding and peptide association of MHC class II molecules on the surface of B cells. J10-1 can be used for research on immunoregulation .
|
-
- HY-182904
-
|
|
HDAC
Collagen
Interleukin Related
Microtubule/Tubulin
|
Endocrinology
|
|
GV-001 is a selective and orally active HDAC6 inhibitor with an IC50 of 1.18 nM against HDAC6. GV-001 selectively enhances α-tubulin acetylation, reduces sIL-6 and Collagen I levels, suppresses renal cyst growth, and upregulates PC1 expression. GV-001 can be used for the study of autosomal dominant polycystic kidney disease (ADPKD) .
|
-
- HY-160187
-
|
|
Orphan GPCR
Angiotensin Receptor
|
Cardiovascular Disease
|
|
AAA is an orally active 20-HETE receptor antagonist. AAA exerts antihypertensive and organoprotective effects. AAA blocks 20-HETE prohypertensive actions, suppresses intrarenal and circulating angiotensin II levels, and interferes with renin-angiotensin system interactions. AAA attenuates development of, and reverses established, ANG II (HY-13948)-dependent malignant hypertension. AAA reduces albuminuria, glomerulosclerosis, and cardiac hypertrophy linked to malignant hypertension. AAA can be used for the research of malignant hypertension .
|
-
- HY-173148
-
|
|
SARS-CoV
|
Infection
|
|
TKB272 is an orally active and selective antiviral agent targeting the main protease (Mpro) of SARS-CoV-2. It effectively blocks the infection and replication of various SARS-CoV-2 strains, including Omicron variants such as XBB.1.5 and EG.5.1. The enzymatic inhibitory activity of TKB272 shows an IC50 of 0.7 µM (against SARS-CoV-2WK-521 Mpro), and its antiviral activity at the cellular level reaches an EC50 as low as 2.6 nM (against BQ.1.1 strain in HeLahACE2-TMPRSS2 cells), with a cytotoxicity CC50 of 98 µM, indicating no apparent toxicity. In addition, TKB272 significantly suppresses the replication of SARS-CoV-2XBB.1.5 in B6.Cg-Tg(K18-hACE2)2-Prlmn/J transgenic mouse models. TKB272 holds promise for research in the field of SARS-CoV-2 infection .
|
-
- HY-153492A
-
|
AMG 890 sodium; ARC-LPA sodium
|
Small Interfering RNA (siRNA)
|
Inflammation/Immunology
|
|
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .
|
-
- HY-P992445
-
|
|
CD20
|
Cancer
|
|
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
|
-
- HY-126047
-
|
|
NF-κB
Beta-secretase
|
Neurological Disease
|
|
(S)-(-)-Anatabine is an NFκB/BACE-1 inhibitor with blood-brain barrier penetration. (S)-(-)-Anatabine inhibits NFκB activation via phosphorylation of its p65 subunit. (S)-(-)-Anatabine inhibits BACE-1 transcription and reduces BACE-1 protein levels. (S)-(-)-Anatabine lowers production of Aβ1-40 and Aβ1-42 by reducing β-cleavage of amyloid precursor protein without affecting α-cleavage. (S)-(-)-Anatabine can be used for the research of Alzheimer's disease .
|
-
- HY-150520
-
|
|
Antibiotic
Phospholipase
|
Infection
Cancer
|
|
Neomycin, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin is a known phospholipase C (PLC) inhibitor. Neomycin potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin can be used for the research of cancer .
|
-
- HY-B0470
-
|
|
Environmental Pollutants
Antibiotic
Phospholipase
Bacterial
|
Infection
Metabolic Disease
Cancer
|
|
Neomycin sulfate, an aminoglycoside antibiotic, exerts antibacterial activity through irreversible binding of the nuclear 30S ribosomal subunit, thereby blocking bacterial protein synthesis. Neomycin sulfate is a known phospholipase C (PLC) inhibitor. Neomycin sulfate potently inhibits both the nuclear translocation of angiogenin and angiogenin-induced cell proliferation and angiogenesis. Neomycin sulfate inhibits IP3-mediated Ca 2+ release, MgATP-dependent Ca 2+ uptake, and electrical excitation-evoked skeletal muscle Ca 2+ transients. Neomycin sulfate depletes gut microbiota in specific mouse models, causes hearing impairment, and kidney damage with prolonged exposure. Neomycin sulfate can be used for the research of cancer .
|
-
- HY-P99653A
-
|
VAY-736 (FUT8-KO)
|
TNF Receptor
Apoptosis
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
|
-
- HY-N6043
-
|
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
Infection
Neurological Disease
Inflammation/Immunology
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
- HY-B0696
-
|
NO050328; NO328; TGB
|
GABA Receptor
|
Neurological Disease
|
|
Tiagabine (NO050328; NO328; TGB) is an orally active, highly selective, and reversible GAT-1 inhibitor and anticonvulsant that crosses the blood-brain barrier. By blocking the reuptake of GABA in neurons and glial cells, tiagabine increases extracellular GABA levels to enhance inhibitory signal transduction, thereby exerting multiple activities such as anticonvulsant, neuroprotective, and antioxidant effects. Tiagabine exhibits linear pharmacokinetic properties. Although it is metabolized by CYP3A and has a high protein binding rate, it carries a low risk of cognitive impairment. Tiagabine is widely used in research on related diseases including epilepsy (including refractory partial seizures), alcohol withdrawal symptoms, and Huntington's disease .
|
-
- HY-162712
-
|
|
Orexin Receptor (OX Receptor)
Tau Protein
|
Neurological Disease
|
|
OX-201 is an orally active, blood-brain barrier-permeable OX2R agonist with an EC50 of 8.0 nM. OX-201 activates OX2R to induce wakefulness and neuronal activation. OX-201 promotes the release of neuron activity-dependent tau protein from neurons into the interstitial fluid of hippocampal tissues. OX-201 is applicable to research related to Alzheimer's disease and tauopathies .
|
-
- HY-107401
-
|
SCH-351125
|
HIV
CCR
Calcium Channel
|
Infection
|
|
Ancriviroc (SCH-351125) is an orally active CCR5 antagonist with an IC50 value of 13 nM against hCCR5. Ancriviroc specifically binds to hCCR5, blocks ligand-induced signal transduction, calcium influx, GTPγS binding, chemotaxis, ligand binding, and HIV-1 entry, induces conformational changes in CCR5, and inhibits infection and replication of R5-tropic HIV-1 .
|
-
- HY-B0590S
-
|
Ro 1-9569-d6
|
Monoamine Transporter
|
Neurological Disease
|
|
Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .
|
-
- HY-B0590R
-
|
Ro 1-9569 (Standard)
|
Reference Standards
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Tetrabenazine (Standard) is the analytical standard of Tetrabenazine (HY-B0590). This product is intended for research and analytical applications. Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-B0512
-
|
RP2632
|
Antibiotic
Bacterial
α-synuclein
|
Infection
Neurological Disease
|
|
Sulfamerazine (RP2632) is a brain-penetrant and orally active sulfonamide antibiotic and α-synuclein inhibitor with human α-synuclein KD of 352 μM. Sulfamerazine inhibits the synthesis of dihydrofolate by bacteria, thereby inhibiting bacterial growth. Sulfamerazine inhibits α-synuclein fibrillation, reduces α-synuclein aggregation-associated toxicity and α-synuclein aggregate accumulation. Sulfamerazine can be used for the research of Parkinson’s disease and bacterial infection .
|
-
- HY-B0590
-
|
Ro 1-9569
|
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-B0590E
-
|
Ro 1-9569 mesylate
|
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Tetrabenazine (Ro 1-9569) mesylate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine mesylate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine mesylate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine mesylate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-B0590S3
-
|
TBZ-d7-d7; Ro 1-9569-d7
|
Isotope-Labeled Compounds
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Tetrabenazine-d7 (TBZ-d7-d7) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-N8279
-
|
Endo-β-1,3-1,4-glucanase
|
Glycosidase
|
Metabolic Disease
|
|
β-1,3-1,4-glucanase (Endo-β-1,3-1,4-glucanase) is a glycoside hydrolase family 16 enzyme (some members belong to subfamily 25). β-1,3-1,4-glucanase shows high substrate specificity toward mixed‑linked β‑glucans and cleaves β‑1,4 glycosidic bonds adjacent to β‑1,3 linkages in an endo‑type pattern. β-1,3-1,4-glucanase can be used in industrial enzyme applications and monogastric animal feed supplementation .
|
-
- HY-116968
-
|
|
Sigma Receptor
|
Neurological Disease
|
|
JVW-1009 is a Sig2R/PGRMC1 antagonist (Sig1R Ki = 96 nM; Sig2R Ki = 70 nM). JVW-1009 acts as a neuroprotective agent. JVW-1009 can be used in the research of Alzheimer's disease .
|
-
- HY-B0590A
-
|
Ro 1-9569 Racemate
|
Monoamine Transporter
Dopamine Receptor
|
Neurological Disease
|
|
Tetrabenazine (Ro 1-9569) Racemate is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine Racemate binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine Racemate weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine Racemate can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
- HY-N0430
-
|
Coptisin
|
Indoleamine 2,3-Dioxygenase (IDO)
NF-κB
p38 MAPK
PI3K
Akt
Apoptosis
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
DNA/RNA Synthesis
ROCK
LDLR
|
Cardiovascular Disease
Neurological Disease
Metabolic Disease
Inflammation/Immunology
Cancer
|
|
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .
|
-
- HY-D3182
-
|
|
Fluorescent Dye
Aldehyde Dehydrogenase (ALDH)
|
Cancer
|
|
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDH bright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer .
|
-
- HY-P99648A
-
|
BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
- HY-134858
-
|
A1AT modulator 1
|
Serpin
Ser/Thr Protease
|
Metabolic Disease
|
|
GSK716 (A1AT modulator 1) is an orally active Z α1-antitrypsin (Z-A1AT) inhibitor with a pIC50 of 8.3. GSK716 binds a cryptic Z α1-antitrypsin pocket, stabilizes monomeric folding intermediates, blocks polymerization, and increases monomer secretion. GSK716 acts on select sensitive α1-antitrypsin variants but fails to affect resistant variants. GSK716 can be used for the research of α1-antitrypsin deficiency and α1-antitrypsin deficiency-associated liver disease .
|
-
- HY-P992057
-
|
|
Tau Protein
|
Neurological Disease
|
|
Armanezumab is a pathological tau protein inhibitor that specifically binds to the N-terminal domain exposed by pathological tau protein (epitope covering amino acids 4-8: PRQEF). Armanezumab is applicable to research related to Alzheimer's disease, frontotemporal dementia, and Pick's disease .
|
-
- HY-P5081
-
|
|
TGF-β Receptor
Collagen
|
Inflammation/Immunology
|
|
Endotrophin (Mus musculus) is an adipokine, a cleavage fragment derived from Collagen VI, whose levels are elevated in adipose tissue and breast tumors of obese mice. Endotrophin (Mus musculus) activates the TGF-β signaling pathway and reduces the expression of hormone-sensitive lipase. Endotrophin (Mus musculus) induces adipogenesis, lipid accumulation, fibrosis, inflammation, angiogenesis, adipose tissue expansion, epithelial-mesenchymal transition, and insulin resistance; it also induces Cisplatin (HY-17394) resistance in cancer cells. Endotrophin (Mus musculus) can be used in research related to metabolic diseases such as obesity and type 2 diabetes, as well as cancers such as breast cancer .
|
-
- HY-112974
-
|
GSK-2998728; ISIS-420915
|
Transthyretin (TTR)
|
Cardiovascular Disease
Neurological Disease
|
|
Inotersen (GSK-2998728; ISIS-420915) is a 2'-O-methoxyethyl-modified antisense oligonucleotide and transthyretin (TTR) inhibitor with low genotoxicity. Inotersen triggers RNase H1-mediated degradation by binding to TTR mRNA, thereby effectively reducing the production of both mutant and wild-type transthyretin in the liver. Inotersen significantly reduces amyloid fiber deposition, yet specific toxicities such as inflammation or tumors are observed at high doses in some animal models. Inotersen is used in studies of hereditary transthyretin amyloidosis and the associated polyneuropathy and cardiomyopathy .
|
-
- HY-P992061
-
|
|
CD3
Calcium Channel
|
Inflammation/Immunology
|
|
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes .
|
-
- HY-P992152
-
|
|
Factor VIIa
Drug Derivative
|
Cardiovascular Disease
|
|
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
|
-
- HY-186073
-
|
|
HDAC
|
Neurological Disease
|
|
HDAC1 activator-1 is a specific HDAC1 activator with orally activity, exerting no significant effects on other HDAC family members. HDAC1 activator-1 exhibits neuroprotective activity, ameliorates cognitive and motor function deficits by reducing neuronal loss and gliosis. HDAC1 activator-1 specifically activates HDAC1 in SH-SY5Y cells and exerts regulatory effects on aberrant cell cycle and DNA damage. HDAC1 activator-1 can be used for the research of TDP-43 proteinopat1-related neurodegenerative diseases including Amyotrophic Lateral Sclerosis (ALS) and cerebral ischemia-related neurological injury .
|
-
| Cat. No. |
Product Name |
Type |
-
- HY-20457G
-
|
|
Fluorescent Dyes
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-D3182
-
|
|
Fluorescent Dyes
|
|
AldeRed 588-A is a fluorescent labeling reagent and a substrate for aldehyde dehydrogenase (ALDH). AldeRed 588-A is metabolized by functionally active ALDH enzymes, thereby specifically labeling viable ALDH bright cell populations with red-shifted fluorescence. AldeRed 588-A supports one-step isolation and sorting of ALDH-expressing cells (including normal stem cells and cancer stem cells), and can be used in combination with green fluorophores for multicolor experimental applications. AldeRed 588-A is widely applicable to research related to various cancers such as bladder cancer, breast cancer, and head and neck cancer .
|
| Cat. No. |
Product Name |
Type |
-
- HY-110002
-
LFM-A13
1 Publications Verification
|
Biochemical Assay Reagents
|
|
LFM-A13 is a potent BTK, JAK2, PLK inhibitor, inhibits recombinant BTK, Plx1 and PLK3 with IC50s of 2.5 μM, 10 μM and 61 μM. LFM-A13 has antiproliferative activity and anticancer activity. LFM-A13 can be used in cancer-related research
|
-
- HY-124187
-
|
Ethyl pinolenate
|
Biochemical Assay Reagents
|
|
Pinolenic acid is a polyunsaturated fatty acid found in the seed oils of red pine (Pinus orientalis) and maritime pine (Pinus pinaster). Both oils were found to have lipid-lowering properties. A diet containing marine pine nut oil (MPSO) reduces HDL and ApoA1 levels in transgenic mice expressing human ApoA1. MPSO was found to reduce cholesterol efflux in vitro. Korean pine nut oil supplements may help obesity by reducing appetite. People who take this oil experience an increase in the satiety hormones CCK and GLP-1 and a decrease in appetite. The activity of the oil is attributed to pinolenic acid. Pinolenic acid is not metabolized to arachidonic acid and can reduce the level of arachidonic acid in the phosphatidylinositol fraction of HepG2 cells from 15.9% to 7.0%. Pinolenic acid ethyl ester is a neutral, more lipophilic form of the free acid.
|
-
- HY-20457G
-
|
|
Biochemical Assay Reagents
|
|
TL8-506 (GMP) is TL8-506 (HY-20457) produced by using GMP guidelines. GMP small molecules work appropriately as an auxiliary reagent for cell therapy manufacture. TL8-506 is a specific TLR8 agonist with an EC50 of 30?nM. TL8-506 has immunomodulatory effects and can be used in the study of tuberculosis and cancer immunotherapy .
|
-
- HY-172503
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
- HY-172503A
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG3400-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG3400-KAA can be used for drug delivery .
|
-
- HY-172504
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG5000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG5000-KAA can be used for drug delivery .
|
-
- HY-172502
-
|
|
Biochemical Assay Reagents
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
| Cat. No. |
Product Name |
Target |
Research Area |
-
- HY-P4885
-
|
AβpE3-40
|
Amyloid-β
|
Neurological Disease
|
|
Glp-Amyloid-β (3-40) Peptide (human) (AβpE3-40) is a minor amounts of pyroglutamate-modified Aβ isolated from from 24-month-old Amyloid precursor protein (APP) transgenic Mice .
|
-
- HY-P5488
-
|
|
Peptides
|
Others
|
|
BDC2.5 Mimotope 1040-63 is a biological active peptide. (The TCR transgenic model (BDC2.5) mimitope was used in type 1 diabetes (T1D) study. T1D is an autoimmune disease in which T cells mediate damage to pancreatic islet b cells. T1D is caused by autoreactive T cell destruction of insulin-producing cells. BDC2.5 mimotope was utilized to support the study on antigen presentation of antigenic peptides to islet autoantigen-specific T cells.)
|
-
- HY-P5081
-
|
|
TGF-β Receptor
Collagen
|
Inflammation/Immunology
|
|
Endotrophin (Mus musculus) is an adipokine, a cleavage fragment derived from Collagen VI, whose levels are elevated in adipose tissue and breast tumors of obese mice. Endotrophin (Mus musculus) activates the TGF-β signaling pathway and reduces the expression of hormone-sensitive lipase. Endotrophin (Mus musculus) induces adipogenesis, lipid accumulation, fibrosis, inflammation, angiogenesis, adipose tissue expansion, epithelial-mesenchymal transition, and insulin resistance; it also induces Cisplatin (HY-17394) resistance in cancer cells. Endotrophin (Mus musculus) can be used in research related to metabolic diseases such as obesity and type 2 diabetes, as well as cancers such as breast cancer .
|
-
- HY-P1787
-
|
|
Amyloid-β
|
Neurological Disease
|
|
β-Amyloid (4-10) is an epitope for the polyclonal anti-Aβ(1-42) antibody, reduces amyloid deposition in a transgenic Alzheimer disease mouse model .
|
-
- HY-P1735
-
-
- HY-P11677
-
|
|
|
Neurological Disease
|
|
CPO_Aβ17-21P is a apoE/Aβ interaction inhibitor with an IC50 of 1.02 nM. CPO_Aβ17-21P significantly inhibits ApoE4-mediated aggregation of Aβ40 and Aβ42. CPO_Aβ17-21P significantly improves cognitive function and comprehensively alleviates Alzheimer's disease (AD)-related pathologies in mouse models. CPO_Aβ17-21P is applicable to the research of AD .
|
| Cat. No. |
Product Name |
Target |
Research Area |
Image |
-
- HY-P99156
-
|
BMS-986016
|
LAG-3
|
Cancer
|
|
Relatlimab (BMS-986016) is a human monoclonal antibody anti-LAG-3 antibody generated by immunization of transgenic mice bearing human immunoglobulin miniloci with recombinant LAG-3 protein. Relatlimab blocks LAG-3/MHC II interaction with an IC50 value of 0.67 nM and LAG-3/FGL1 interaction with an IC50 value of 0.019 nM. Relatlimab can be used in research of cancer .
|
-
(5)
-
- HY-P99022
-
|
R-04909832; RG-1450
|
Amyloid-β
|
Neurological Disease
|
|
Gantenerumab is a fully humanized anti-Aβ IgG1 monoclonal antibody. Gantenerumab can specifically bind to Aβ fibrils and plaques and can be used in Alzheimer's disease research .
|
-
(5)
-
- HY-P990094
-
|
CSL311
|
c-Fms
|
Inflammation/Immunology
|
|
Trabikibart (CSL311) is a specific inhibitor targeting the βc receptor (CSF2RB) that inhibits signal transduction mediated by GM-CSF, IL-5, and IL-3. Trabikibart exhibits significant anti-inflammatory and anti-edema effects, reduces myeloid cell infiltration, and inhibits inflammatory cell survival. Trabikibart also possesses antiviral immune functions, which alleviate pulmonary inflammation, reverse airway dysfunction and fibrosis, and thereby restore impaired pulmonary function. Trabikibart can be used in research on related diseases such as acute respiratory distress syndrome, viral pneumonia, asthma, and chronic rhinosinusitis with nasal polyps .
|
-
(5)
-
- HY-P99653A
-
|
VAY-736 (FUT8-KO)
|
TNF Receptor
Apoptosis
NF-κB
|
Inflammation/Immunology
Cancer
|
|
Ianalumab (VAY-736) (FUT8-KO) is an anti-BAFF-R monoclonal antibody expressed in CHO cells with the fucosyltransferase 8 gene (FUT8) knocked out. Fucose depletion enhances its B cell clearance capacity. Ianalumab (FUT8-KO) competitively blocks the binding of BAFF to BAFF-R, inhibits the BAFF-mediated alternative NF-κB pro-survival signaling pathway, and abrogates the apoptotic (apoptosis) protective effect of BAFF on cancer cells. Ianalumab (FUT8-KO) can be used in research related to primary Sjögren's syndrome and chronic lymphocytic leukemia .
|
-
(5)
-
- HY-P991307
-
|
|
LILRB
Transmembrane Glycoprotein
|
Cancer
|
|
BND-35 is a human monoclonal antibody (mAb) targeting LILRB4/ILT3/CD85k. BND-35 blocks the interaction of ILT3 with APOE and fibronectin, enhances the pro-inflammatory activity of various myeloid cells, and reverses ILT3-mediated immunosuppression of T cells by various suppressive myeloid cells. BND-35 has anti-tumor activity in the hILT3 transgenic mouse tumor model .
|
-
(5)
-
- HY-P991592
-
|
|
Inhibitory Antibodies
|
Inflammation/Immunology
|
|
UB-221 is a humanized IgG1 monoclonal antibody inhibitor targeting IgE. UB-221 significantly decreases IgE synthesis by stabilization of membrane-bound CD23 on B lymphocytes and inhibits FcԑRI-mediated basophil activation and degranulation. UB-221 reduces IgE level in cynomolgus macaques and human IgE (ε, κ)-transgenic (hIGHE-knockin) mice. UB-221 can be used for asthma and chronic spontaneous urticaria (CSU) research .
|
-
(5)
-
- HY-P991587
-
|
|
Orphan GPCR
|
Cancer
|
|
SAR-446523 is a humanized IgG1 monoclonal antibody inhibitor targeting GPRC5D. SAR-446523 significantly induces antibody-dependent cell-mediated cytotoxicity (ADCC). SAR-446523 has potent antitumor activity with improvement of mouse survival in NK humanized NOG huIL15 transgenic mice model bearing MM cells. SAR-446523 can be used for multiple myeloma (MM) research .
|
-
(5)
-
- HY-P992484
-
|
|
Tau Protein
|
Neurological Disease
|
|
VY7523 is a monoclonal antibody and a selective inhibitor of pathological Tau. VY7523 reduces the propagation of pathogenic Tau in transgenic mouse models. VY7523 can be used in the research of Alzheimer's disease. The isotype control is Human IgG4 (S228P) kappa, Isotype Control (HY-P99003) .
|
-
(5)
-
- HY-P991918
-
|
IgG2-AAS
|
Transmembrane Glycoprotein
Interleukin Related
|
Inflammation/Immunology
Cancer
|
|
KHK2840 is a potent CD40 agonist with a Kd value of 0.485 nM for hCD40. KHK2840 delivers agonistic signals in tumor-bearing hCD40 transgenic mice and human peripheral blood B cells. KHK2840 upregulates CD80, CD86, CD95 and IL-12p70 expression. KHK2840 enhances antitumor efficacy of anti-PD-1 antibody and Paclitaxel (HY-B0015). KHK2840 can be used for the research of cancer, such as colon cancer and melanoma .
|
-
(5)
-
- HY-P991528
-
|
|
NF-κB
|
Inflammation/Immunology
Cancer
|
|
PE0116 is a fully human CD137 agonistic monoclonal antibody generated from immunized harbor H2L2 human transgenic mice. PE0116 is a ligand block. PE0116 activates NF-κB signaling which significantly promotes T-cell proliferation and increases cytokine secretion in vitro. PE0116 exhibits robust antitumor activity in MC38 tumor model .
|
-
(5)
-
- HY-P991867
-
|
|
Amyloid-β
|
Neurological Disease
|
|
SHR-1707 is a humanized anti-Aβ IgG1 monoclonal antibody. SHR-1707 binds Aβ fibrils and monomers, blocking plaque formation and promoting the microglial phagocytosis of Aβ. SHR-1707 reduces brain Aβ deposition in 5xFAD transgenic mice. SHR-1707 can be used for Alzheimer’s disease research. Recommend Isotype Controls: Human IgG1 kappa, Isotype Control (HY-P99001) .
|
-
(5)
-
- HY-P992455
-
|
|
CD38
Fc Receptor (FcR)
Apoptosis
|
Cancer
|
|
SAR442085 is an Fc-engineered anti-CD38 monoclonal antibody with a Kd of 0.2 nM for human CD38. SAR442085 inhibits CD38, induces apoptosis, and triggers antibody-dependent cellular cytotoxicity and phagocytosis in CD38-expressing tumor cells. SAR442085 binds allelic variants of FcγRIIa and FcγRIIIa, enhances NK cell activation, degranulation and cytokine secretion, and exerts anti-tumor activity in human Fc receptor transgenic mice. SAR442085 can be used in the research of multiple myeloma .
|
-
(5)
-
- HY-P992388
-
|
|
LILRB
|
Cancer
|
|
IO-108 is a humanized IgG4 monoclonal antibody and a competitive inhibitor of LILRB2, with a KD value of 1.97 nM. IO-108 competitively blocks the binding of LILRB2 to its ligands including HLA-G, MHC-I, ANGPTL2 and SEMA4A, reprograms tumor-associated myeloid cells, drives the conversion of suppressive myeloid cells into a pro-inflammatory phenotype, and restores the cytotoxic activity of T cells and NK cells. IO-108 inhibits tumor growth in LILRB2 transgenic mouse models. IO-108 can be used for the research of solid tumors .
|
-
(5)
-
- HY-P992156
-
|
|
LAG-3
|
Cancer
|
|
Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) is a monoclonal antibody that specifically binds to human, mouse and bovine LAG-3. Anti-Human/Mouse/Bovine LAG-3 Antibody (ADI-31853) can be used in the research of colon cancer, colorectal cancer and rectal cancer .
|
-
(5)
-
- HY-P992445
-
|
|
CD20
|
Cancer
|
|
PRO131921 is a humanized IgG1 anti-CD20 antibody, with antibody-dependent cellular cytotoxicity and complement-dependent cytotoxicity activities. PRO131921 acts as an anti-tumor agent. PRO131921 can be used for the research of indolent non-Hodgkin lymphoma and relapsed and refractory indolent lymphoma .
|
-
(5)
-
- HY-P99648A
-
|
BMS-986168 (powder); IPN007 (powder); BIIB092 (powder)
|
Tau Protein
|
Neurological Disease
|
|
Gosuranemab (BMS-986168; IPN007; BIIB092) (powder) is a humanised IgG4 anti-tau monoclonal antibody. Gosuranemab (powder) neutralizes the extracellular tau protein, inhibiting the spread and aggregation of pathological tau protein. Gosuranemab (powder) can be used for the research of progressive supranuclear palsy and early Alzheimer’s disease .
|
-
(5)
-
- HY-P992057
-
|
|
Tau Protein
|
Neurological Disease
|
|
Armanezumab is a pathological tau protein inhibitor that specifically binds to the N-terminal domain exposed by pathological tau protein (epitope covering amino acids 4-8: PRQEF). Armanezumab is applicable to research related to Alzheimer's disease, frontotemporal dementia, and Pick's disease .
|
-
(5)
-
- HY-P992061
-
|
|
CD3
Calcium Channel
|
Inflammation/Immunology
|
|
Anti-Mouse CD3E Antibody (500A2) is an antibody targeting mouse CD3ε, which specifically binds to the region on CD3ε adjacent to the T cell receptor binding site. Anti-Mouse CD3E Antibody (500A2) triggers functional signal transduction in immature T cells and activates naive T cells. When cross-linked, Anti-Mouse CD3E Antibody (500A2) induces a rapid, robust and transient increase in cytoplasmic calcium concentration, acting as a potent calcium flux inducer. Anti-Mouse CD3E Antibody (500A2) is suitable for multiple experimental techniques such as flow cytometry, immunoprecipitation and EMARS reactions. It can be used to detect CD3E expression on thymocytes, mature T lymphocytes and NK-T cells from different mouse strains, or to identify membrane cluster components of the TCR complex, and shows no cross-reactivity with rat leukocytes .
|
-
(5)
-
- HY-P992152
-
|
|
Factor VIIa
Drug Derivative
|
Cardiovascular Disease
|
|
Vatreptacog alfa is a recombinant hFVIIa analog, differing from native FVIIa by three amino acid substitutions (V158D, E296V and M298Q) in the protease domain. Vatreptacog alfa exhibits enhanced tissue factor-independent enzymatic activity toward activated platelets. Vatreptacog alfa can be used in the research of hemophilia .
|
-
(5)
| Cat. No. |
Product Name |
Category |
Target |
Chemical Structure |
-
- HY-B0470
-
-
-
- HY-123033A
-
-
-
- HY-N6608
-
-
-
- HY-123033
-
-
-
- HY-B0957
-
-
-
- HY-N4150
-
-
-
- HY-N1534
-
-
-
- HY-N6043
-
|
|
Structural Classification
Canarium album (Lour.) Rauesch.
Classification of Application Fields
Phenols
Polyphenols
Plants
Burseraceae
Inflammation/Immunology
Disease Research Fields
Source Classification
|
Apoptosis
Reactive Oxygen Species (ROS)
Bacterial
SARS-CoV
Estrogen Receptor/ERR
|
|
Hydroxytyrosol acetate is an orally active, blood-brain barrier-permeable multi-active compound with multiple effects including antibacterial, antioxidant, anti-platelet aggregation, and neuroprotective activities. Hydroxytyrosol acetate not only inhibits the growth of Vibrio by increasing bacterial membrane permeability, but also interacts with DNA and mediates supercoiled DNA relaxation. Meanwhile, Hydroxytyrosol acetate effectively reduces thrombosis and inhibits lipid oxidation by inhibiting COX activity and promoting vascular nitric oxide production. In terms of neuroprotection, Hydroxytyrosol acetate significantly alleviates neuronal apoptosis and inflammatory responses by up-regulating the expression level of ERβ, thereby improving cognitive function in Alzheimer's disease models. Hydroxytyrosol acetate has been widely used in scientific research related to Vibrio infection, arterial thrombosis, Alzheimer's disease and other related fields .
|
-
-
- HY-N0430
-
|
Coptisin
|
Alkaloids
Structural Classification
Classification of Application Fields
Coptis chinensis Franch.
Ranunculaceae
Metabolic Disease
Quinoline Alkaloids
Plants
Disease Research Fields
Source Classification
|
Indoleamine 2,3-Dioxygenase (IDO)
NF-κB
p38 MAPK
PI3K
Akt
Apoptosis
Reactive Oxygen Species (ROS)
Mitochondrial Metabolism
DNA/RNA Synthesis
ROCK
LDLR
|
|
Coptisine is an orally active and brain-penetrant alkaloid found in Coptis chinensis. Coptisine is a reversible, uncompetitive IDO inhibitor with a Ki of 5.8 μM and an IC50 of 6.3 μM. Coptisine suppresses neuroinflammation, reduces Aβ plaque burden and shows neuroprotective activity. Coptisine shows anti-inflammation activity by blocking NF-κB, MAPK, and PI3K/Akt activation. Coptisine inhibits cancer cells proliferation, induces DNA damage, G2/M phase cell cycle arrest, apoptosis, ROS production and mitochondrial dysfunction. Coptisine inhibits Rho/ROCK pathway activation, reduces arrhythmia, limits cardiac injury marker release, reduces infarct size, and preserves cardiac function in rat myocardial ischemia/reperfusion models. Coptisine downregulates HMGCR and upregulates LDLR and CYP7A1 to modulate cholesterol metabolism, reduces abnormal serum lipid levels, and promotes fecal bile acid excretion. Coptisine can be used for the research of cancer, hypercholesterolemia, Alzheimer’s disease, inflammatory disorders and cardiovascular disease .
|
-
-
- HY-W011151
-
-
-
- HY-123033C
-
-
-
- HY-123033AR
-
|
|
Alkaloids
Structural Classification
Animals
Pyridine Alkaloids
Source Classification
|
Reference Standards
Sirtuin
Endogenous Metabolite
|
|
Nicotinamide riboside (chloride) (Standard) is the analytical standard of Nicotinamide riboside (chloride). This product is intended for research and analytical applications. Nicotinamide riboside Chloride, an orally active NAD+ precursor, increases NAD+ levels and activates SIRT1 and SIRT3. Nicotinamide riboside Chloride is a source of vitamin B3 (niacin) and enhances oxidative metabolism, protection against high fat diet-induced metabolic abnormalities[1]. Nicotinamide riboside Chloride reduces cognitive deterioration in a transgenic mouse model of Alzheimer’s disease[2].
|
-
-
- HY-N0542
-
-
-
- HY-123033B
-
-
-
- HY-12372
-
-
-
- HY-N1414A
-
|
|
Natural Products
Polymer products
Plants
Brassicaceae
Raphanus sativus Linn.
|
Bcl-2 Family
Apoptosis
|
|
3′,6-Disinapoylsucrose is a type of oligosaccharide that's effective when taken orally, and it has antidepressant, anti-anxiety, and antioxidant properties. 3′,6-Disinapoylsucrose inhibits neuronal apoptosis by lowering the ratio of Bax to Bcl-2 in hippocampal neurons, and it enhances cognitive function in APP/PS1 transgenic mice by activating the CREB/BDNF signaling pathway .
|
-
-
- HY-122989
-
-
-
- HY-N4150R
-
|
Quercetagetin-7-O-glucoside (Standard)
|
Flavonols
Structural Classification
Flavonoids
Erythrina melanacantha Taub. ex Harms
Phenols
Polyphenols
Plants
Compositae
Source Classification
|
Reference Standards
Phosphatase
Tau Protein
NF-κB
|
|
Quercetagitrin (Standard) is the analytical standard of Quercetagitrin. This product is intended for research and analytical applications. Quercetagitrin (Quercetagetin-7-O-glucoside) is a natural product that can be isolated from the African marigold (Tagetes erecta). Quercetagitrin has anti-inflammatory activity. Quercetagitrin inhibits Tau accumulation. Quercetagitrin can reverse neuroinflammation and cognitive deficits in P301S-Tau transgenic mouse model through inhibiting NF-κB activation. Quercetagitrin is a dual-target inhibitor of PTPN6 (IC50 = 1 μM) and PTPN9 (IC50 = 1.7 μM). Quercetagitrin enhances glucose uptake by mature C2C12 myoblasts. Quercetagitrin can be studied in research for Alzheimer’s disease and type 2 diabetes .
|
-
-
- HY-N19612
-
-
-
- HY-N17667
-
-
| Cat. No. |
Product Name |
Chemical Structure |
-
- HY-B0590S
-
|
|
|
Tetrabenazine-d6 (Deutetrabenazine) is a deuterium-labled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
-
- HY-N6608S
-
|
|
|
Physostigmine-d3 is the deuterium labeled Physostigmine. Physostigmine (Eserine) is a reversible acetylcholinesterase (AChE) inhibitor. Physostigmine can crosses the blood-brain barrier and stimulates central cholinergic neurotransmission. Physostigmine can reverse memory deficits in transgenic mice with Alzheimer's disease. Physostigmine is also an antidote for anticholinergic poisoning .
|
-
-
- HY-13757S
-
|
|
|
Tamoxifen-d3 hydrochloride is deuterated labeled Tamoxifen (Citrate) (HY-13757). Tamoxifen Citrate (ICI 46474) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells .Tamoxifen Citrate is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen Citrate also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen Citrate activates autophagy and induces apoptosis .Tamoxifen Citrate also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
-
- HY-B0531S
-
|
|
|
Triflusal-d3 is deuterium labeled Triflusal (HY-B0531). Triflusal is an orally bioavailable, blood-brain barrier-permeable dual Cyclooxygenase-1 (COX-1)/cAMP phosphodiesterase inhibitor. Triflusal inhibits platelet aggregation, NF-κB activation, iNOS activity, and prostaglandin synthesis in ischaemic tissue. Triflusal stimulates neutrophil nitric oxide production, eNOS protein expression, and cNOS activity. Triflusal alleviates cerebral ischemic injury in rats and ameliorates pathological lesions and related gene expression in transgenic Alzheimer’s disease models. Triflusal can be used for the research of thromboembolic/ischemic cardiovascular and cerebrovascular diseases, and Alzheimer’s disease .
|
-
-
- HY-13757AS1
-
|
|
|
Tamoxifen-d3 is the deuterium labeled Tamoxifen . Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER(T2) transgenic mouse .
|
-
-
- HY-W778408
-
|
|
|
Tamoxifen- 13C6 (ICI 47699- 13C6) is the 13C-labeled Tamoxifen (HY-13757A). Tamoxifen (ICI 47699) is an orally active, selective estrogen receptor modulator (SERM) which blocks estrogen action in breast cells and can activate estrogen activity in other cells, such as bone, liver, and uterine cells . Tamoxifen is a potent Hsp90 activator and enhances the Hsp90 molecular chaperone ATPase activity. Tamoxifen also potent inhibits infectious EBOV Zaire and Marburg (MARV) with IC50 of 0.1 μM and 1.8 μM, respectively . Tamoxifen activates autophagy and induces apoptosis . Tamoxifen also can induce gene knockout of CreER transgenic mouse .
|
-
-
- HY-B0590S3
-
|
|
|
Tetrabenazine-d7 (TBZ-d7-d7) is deuterium labeled Tetrabenazine (HY-B0590). Tetrabenazine (Ro 1-9569) is a brain-penetrant and orally active VMAT2-selective ligand with human VMAT2 Ki 100 nM. Tetrabenazine binds VMAT2 to block monoamine uptake into synaptic vesicles, potentiates cytoplasmic monoamine degradation. Tetrabenazine weakly blocks dopamine D2 receptors, and increases dopamine turnover via elevated cerebrospinal fluid homovanillic acid. Tetrabenazine can be used for the research of Huntington’s disease, tardive dyskinesia, and Tourette’s syndrome .
|
-
| Cat. No. |
Product Name |
|
Classification |
-
- HY-112974
-
|
GSK-2998728; ISIS-420915
|
|
Antisense Oligonucleotides
|
|
Inotersen (GSK-2998728; ISIS-420915) is a 2'-O-methoxyethyl-modified antisense oligonucleotide and transthyretin (TTR) inhibitor with low genotoxicity. Inotersen triggers RNase H1-mediated degradation by binding to TTR mRNA, thereby effectively reducing the production of both mutant and wild-type transthyretin in the liver. Inotersen significantly reduces amyloid fiber deposition, yet specific toxicities such as inflammation or tumors are observed at high doses in some animal models. Inotersen is used in studies of hereditary transthyretin amyloidosis and the associated polyneuropathy and cardiomyopathy .
|
-
- HY-153492A
-
|
AMG 890 sodium; ARC-LPA sodium
|
|
siRNAs
siRNA drugs
|
|
Olpasiran (AMG 890, ARC-LPA) sodium is an N-acetyl galactosamine (GalNAc)-conjugated, hepatocyte-targeted siRNA. Olpasiran sodium directly inhibits LPA messenger RNA translation in hepatocytes and potently reduce Lp(a) concentration. Olpasiran sodium can be used for the research of cardiovascular disease, such as atherosclerosis .
|
-
- HY-174790
-
|
|
|
mRNA
Reporter Genes
|
|
Firefly Luciferase mRNA is a reporter mRNA that can be transfected into cells to express firefly luciferase protein. Firefly Luciferase mRNA induces cytotoxicity in cancer cells at low concentrations. In cancer cells, the expression level of luciferase shows a non-linear relationship with the dose of Firefly Luciferase mRNA. When combined with the H2S-responsive bioluminescent probe (H-Luc), Firefly Luciferase mRNA enables bioluminescence-based detection of endogenous hydrogen sulfide in non-transgenic NAFLD cell models and NAFLD mouse models. Firefly Luciferase mRNA can be used in studies related to non-alcoholic fatty liver disease .
|
-
- HY-174795
-
|
|
|
mRNA
Reporter Genes
|
|
mCherry mRNA encodes the mCherry fluorescent protein, which is derived from Anaplasma marginale. mCherry can be used as a fluorescent tracer in transfection and transgenic experiments or as a reporter of gene expression.
|
-
- HY-171953
-
|
|
|
Cationic Lipids
|
|
THP1 Lipid is an ionizable lipidoid. THP1 Lipid can be used to synthesize lipid nanoparticles (LNPs) for delivering mRNA to muscles with minimal toxicity and editing genes in specific liver tissues in tdTomato transgenic mice model. THP1 Lipid can be used for vaccine delivery and CRISPR/Cas9-mediated gene editing research .
|
-
- HY-172503
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG2000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG2000-KAA can be used for drug delivery .
|
-
- HY-172503A
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG3400-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG3400-KAA can be used for drug delivery .
|
-
- HY-172504
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG5000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG5000-KAA can be used for drug delivery .
|
-
- HY-172502
-
|
|
|
Pegylated Lipids
|
|
DSPE-PEG1000-KAA is a PEG compound which composed of DSPE and a CKAAKNK peptide (KAA). KAA specifically binds to tumor vessels in RIP-Tag2 transgenic mice. DSPE-PEG1000-KAA can be used for drug delivery .
|
| Cat. No. |
Product Name |
Target |
Research Areas |
Chemical Structure |
Your information is safe with us. * Required Fields.
Inquiry Information
- Product Name:
- Cat. No.:
- Quantity:
- MCE Japan Authorized Agent:
